Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Nursing Practice Environment and Patient Safety in Primary Health Care

NCT06762015 · tracked via the Priya Life Science Portugal tracker
Sponsor
Cintia Silva Fassarella
Phase
Not applicable
Started
2024-09-02
Last updated
2025-01-07

Condition(s) studied

Healthy Work EnvironmentPatient SafetyPrimary Health Care

Investigational drug(s) / intervention(s)

Positive Nursing Practice Environments Promotion Program

Positive Nursing Practice Environments Promotion Program: A multi-component intervention program aimed at promoting positive nursing practice environments.

Study summary

The goal of this study is to conduct an experimental, controlled, and randomized study, which will involve two data collection points - pre-intervention, post-intervention and a follow-up to asses the impact of the program. The study will be carried out with two groups - an intervention group and a control group, consisting of nurses interested in participating in the Positive Nursing Practice Environments Promotion Program (PAPEP), a multi-component intervention program aimed at promoting positive nursing practice environments. Participant allocation will be conducted randomly, using software to ensure stratified randomization of participants between the two groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Nurses working in primary health care units Exclusion Criteria: * Nurses in primary health care who refuse to participate in the study

Primary outcome measure(s)

  • Work Environment — 6 months
    Scale for the environments evaluation of professional nursing practice-shortened version. The Scale for the Environment's Evaluation of Professional Nursing Practice-Shortened Version consists of 59 items across three subscales: Structure (29 items), Process (19 items), and Outcome (11 items). Participants rate each item on a five-point Likert scale (1: never to 5: always). Higher scores indicate a more favorable nursing practice environment for care quality and professional well-being. Scores are interpreted as follows: \<35% (unfavorable), 35-55% (moderately favorable), 55-75% (favorable), and \>75% (very favorable).
  • Safety climate — 6 months
    Safety Attitudes Questionnaire - Short Form The Safety Attitudes Questionnaire (SAQ) - Short Form 2006 assesses healthcare professionals' perceptions of patient safety attitudes across various clinical areas and healthcare services. It has been validated and culturally adapted to the context in which the study will be conducted. The SAQ - Short Form 2006 comprises six dimensions, addressing organizational factors, work environment factors, and team factors, with a total of 30 items. Participants respond to each item using a five-point Likert scale: "strongly disagree," "partially disagree," "neutral," "partially agree," and "strongly agree." The final score ranges from 0 to 100, where 0 represents the worst perception and 100 the best perception of the safety climate.

Trial sites (1)

FacilityCityRegionStatus
ULS Entre Douro e Vouga Santa Maria da Feira Aveiro District
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06762015 on ClinicalTrials.gov ↗ ← All trials in Portugal